Our Story
About Us
Founded in 2014, Speratum Biopharma is a trailblazing mRNA-focused biopharmaceutical company with a global footprint with headquarters in Dover, Delaware, USA, and San JosĂ©, Costa Rica. Dedicated to revolutionizing cancer treatment, our mission is to “Deliver hope through innovative cancer therapeutics.”
At Speratum, we specialize in developing precision RNA-based medicines to address the most complex and difficult-to-treat cancers. Our groundbreaking work is powered by proprietary, state-of-the-art technologies.
To learn more
At Speratum Biopharma, we are unlocking the full potential of RNA therapies to revolutionize cancer treatment. Our focus is on developing groundbreaking messenger RNA (mRNA), small interfering RNA (siRNA) medicines and gene editing solutions, designed to tackle some of the most challenging cancer indications.
With our proprietary platforms and robust intellectual property portfolio, we are at the forefront of RNA-based drug discovery and development. What sets Speratum Biopharma apart is our team’s unparalleled expertise in RNA drug discovery and development.
Our scientists and innovators have dedicated years to advancing synthetic oligonucleotide biology and creating cutting-edge therapeutic platforms that harness the precision and versatility of mRNA and siRNA. By integrating innovative drug product manufacturing with our scientific capabilities, we are pioneering new approaches to address the unmet needs of patients with hard-to-treat cancers.
Our research and development initiatives are aimed at catalyzing the next wave of breakthroughs in cancer therapeutics. Every step of our journey is guided by our mission: “Delivering hope through innovative cancer therapeutics.”
At Speratum, we are not only creating RNA-based medicines but also shaping the future of oncology by transforming scientific potential into tangible solutions for patients worldwide.